Schonfeld Strategic Advisors’s SpringWorks Therapeutics SWTX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-55,000	Closed	-$2.58M	–	2565
2025 Q2	$2.58M	Buy	55,000 +54,800	+27,400%	+$2.44M	0.02%	841
2025 Q1	$8.83K	Buy	+200	New	+$9.21K	﹤0.01%	2125

Other funds holding SWTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Schonfeld Strategic Advisors's SWTX Position: Q3 2025 in Review

Schonfeld Strategic Advisors sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 42,899 shares — an estimated $2.02M sold.

Schonfeld Strategic Advisors first reported a position in SWTX in Q2 2022 and held it in 10 quarters. The position peaked at $17M in Q4 2023. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

Schonfeld Strategic Advisors reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
Schonfeld Strategic Advisors sold 42,899 SpringWorks Therapeutics shares in Q3 2025, an estimated $2.02M.
Schonfeld Strategic Advisors first reported a position in SpringWorks Therapeutics in Q2 2022 and held it in 10 quarters.
Schonfeld Strategic Advisors's SpringWorks Therapeutics position peaked at $17M in Q4 2023.
3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.